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Objectives This study sought to characterize reasons for surgical ineligibility in patients undergoing
nonemergent unprotected left main (ULM) percutaneous coronary intervention (PCI) and to assess the
potential for these reasons to confound comparative effectiveness studies of coronary revascularization.
Background Although both PCI and coronary artery bypass graft surgery are treatments for ULM dis-
ease, some patients are not eligible for both treatments, which may result in treatment selection biases.
Methods In 101 consecutive patients undergoing nonemergent ULM PCI, mixed methods were
used to determine the prevalence of treatment selection dictated by surgical ineligibility and to
identify the reasons cited for avoiding coronary artery bypass graft surgery. We then determined
whether these reasons were captured by the ACC–NCDR (American College of Cardiology–National
Cardiovascular Data Registry) Cath-PCI dataset to assess the ability of this registry to account for
biases in treatment selection. Finally, the association of surgical eligibility with long-term outcomes
after ULM PCI was assessed.
Results Treatment selection was dictated by surgical ineligibility in over half the ULM PCI cohort with
the majority having reasons for ineligibility not captured by the ACC–NCDR. Surgical ineligibility was a
signiﬁcant predictor of mortality after adjustment for Society of Thoracic Surgeons (hazard ratio [HR]: 5.4,
95% conﬁdence interval [CI]: 1.2 to 25), EuroSCORE (European System for Cardiac Operative Risk Evalua-
tion) (HR: 5.9, 95% CI: 1.3 to 27), or NCDR mortality scores (HR: 6.2, 95% CI: 1.4 to 27).
Conclusions Surgical ineligibility dictating treatment selection is common in patients undergoing
nonemergent ULM PCI, occurs on the basis of risk factors not captured by the ACC–NCDR, and is
independently associated with worse long-term outcomes after adjusting for standard risk
scores. (J Am Coll Cardiol Intv 2011;4:1020–7) © 2011 by the American College of Cardiology
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1021Observational comparisons of coronary artery bypass graft
(CABG) surgical and percutaneous coronary intervention
(PCI) treatment of unprotected left main (ULM) coronary
disease are a burgeoning field in comparative effectiveness
research (1,2). However, all observational comparisons are
potentially limited by differences in baseline conditions that
can affect the treatment choice and lead to treatment
selection bias. If differences that bias treatment choice are
not adjusted for and if they influence outcomes, then these
unrecognized baseline conditions can significantly con-
found, and render inaccurate, such comparisons (3).
See page 1028
Observational studies comparing modes of revasculariza-
tion in left main disease have relied primarily on multivari-
able adjustment or the use of propensity scores to attempt to
account for selection bias in the choice between CABG or
PCI (4–13). However, these methods are limited in that
they rely on measured variables (14), which are typically
traditional risk factors in studies of revascularization for
ULM disease. This is especially true for studies using
administrative or quality assessment data. As any clinician
can attest, the factors that are considered in determining an
individual patient’s candidacy for CABG are often nuanced
and not necessarily captured with standard procedural risk
assessments (15). Even though observational series of ULM
PCI have provided insight into the prevalence of increased
surgical risk and its impact on outcomes, most of these
studies broadly characterized surgical risk or relied on
traditionally measured risk factors or prediction scores
(16–29). There is a paucity of data regarding factors that
guide treatment choice in this population, and the potential
for unmeasured factors to confound observational compar-
isons is unknown.
To address these gaps in knowledge, we sought to: 1) use
clinical data to determine the prevalence of surgical ineligi-
bility dictating treatment choice among patients undergoing
nonemergent ULM PCI; 2) characterize the reasons cited
for surgical ineligibility; 3) determine whether these reasons
are captured by the ACC–NCDR (American College of
Cardiology–National Cardiovascular Data Registry) Cath-
PCI registry; and 4) determine whether surgical ineligibility
is an independent predictor of outcomes and, therefore, a
source of potential confounding in comparative effectiveness
studies relying on ACC NCDR data.
Methods
Study population. This protocol was approved by the Insti-
tutional Review Board of Kaiser Permanente Northern
California (KPNC) and a waiver of informed consent was
granted. The study population included patients without a
history of CABG who underwent PCI for ULM disease(defined as a noniatrogenic, de novo lesion with a diameter
stenosis 50%) between January 2003 and December 2009
at Kaiser Permanente Medical Center, San Francisco. As
the aim of the study was to assess determinants of treatment
selection in a population of patients undergoing evaluation
for either percutaneous or surgical revascularization, pa-
tients in whom clinical urgency resulted in emergent PCI
were excluded, including those with cardiogenic shock,
acute ST-segment elevation myocardial infarction, ongoing
ischemic chest pain, or following cardiac arrest.
Data abstraction and classiﬁcation. Medical records were
independently reviewed by 2 investigators (E.M. and W.N.)
to classify patients by eligibility for CABG as judged by
treating clinicians. The KPNC electronic medical record is
robust and includes progress notes, operative reports, and
discharge summaries, as well as all radiologic and clinical
laboratory data and chronic problem lists. “CABG ineligi-
ble” was coded if the medical record contained documenta-
tion that the patient was not a candidate for CABG, or if
the patient was referred for PCI after a surgical evaluation
concluded that the patient’s sur-
gical risk was excessive. If the
sole reason for choosing PCI
was patient preference, the pa-
tient was coded as “CABG eli-
gible,” regardless of perceived
risk. If there was no explicit
documentation of the suitability
of the patient for surgery, the
patient was also coded as a
“CABG eligible,” regardless of
perceived operative risk. The
classification “CABG eligible”
versus “CABG ineligible” was
not an independent assessment of eligibility for CABG by
the reviewer, but rather an assessment of documentation by
the treating clinicians of each patient’s eligibility for CABG.
Interobserver agreement was assessed using the kappa sta-
tistic. In situations where the 2 investigators disagreed,
consensus was achieved after discussion.
To systematically refine surgical ineligibility as the foun-
dation for selecting PCI, reasons for ineligibility were
extracted and grouped thematically to create a taxonomy.
To mitigate ascertainment bias, the electronic medical
records of all patients were again reviewed to determine the
presence of any of the categorized reasons for surgical
ineligibility in all patients including those classified as
CABG-eligible.
Given the goal to assess the extent to which identified
reasons for surgical ineligibility could be accounted for in
comparative effectiveness research studies, we then estab-
lished whether these reasons were captured by version 3 of
the ACC–NCDR (American College of Cardiology Na-
Abbreviations
and Acronyms
CABG  coronary artery
bypass graft
CI  confidence interval
HR  hazard ratio
KPNC  Kaiser Permanente
Northern California
PCI  percutaneous
coronary intervention
ULM  unprotected left
maintional Cardiovascular Data Registry) Cath-PCI registry.
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1022This registry is a procedural registry used by over 1,000 U.S.
hospitals as part of a quality assessment/improvement pro-
cess and contains information on over 3 million patients
undergoing PCI (30). It is also being used (with version 3
data) for comparative effectiveness studies including the
NIH-funded ASCERT (American College of Cardiology
Foundation–Society of Thoracic Surgeons Collaboration on
the Comparative Effectiveness of Revascularization Strate-
gies) study comparing long-term outcomes of PCI and
CABG (31). Reasons cited for surgical ineligibility were
therefore categorized as “Non-NCDR Captured” or
“NCDR Captured.”
Baseline characteristics, procedural variables, and dis-
charge medications were compared for patients with and
without documentation of surgical ineligibility. Over 130
variables were measured for each patient using definitions as
stipulated by the NCDR, EuroSCORE (European System
for Cardiac Operative Risk Evaluation), or Society of
Thoracic Surgery scores where relevant (see Online Appen-
dix 1 for list of variables extracted). Predicted mortalities
were calculated using the logistic EuroSCORE (32), the
Society of Thoracic Surgery Risk Score (33), and the
NCDR Cath-PCI risk score (34).
Statistical analyses. Continuous variables are presented as
mean  SD or median (interquartile range). Categorical
ariables are presented as number (percentage). The Student
test or Wilcoxon rank-sum test were used to compare
ontinuous variables as appropriate, and the chi-square or
isher exact test were used to compare categorical variables. A
-sided alpha of 0.05 was considered statistically significant.
Long-term clinical outcomes were then compared among
ll ULM PCI patients based on the presence or absence of
urgical ineligibility. The primary outcome endpoint was
ll-cause mortality with secondary endpoints of: 1) com-
ined death, any myocardial infarction, or permanent
troke; and 2) repeat revascularization (CABG or PCI).
ime-to-event analysis was performed with patients con-
idered at risk until the last documented physical encounter
n the electronic medical record. The occurrence of out-
omes was determined by manual chart review. The KPNC
lectronic medical record contains very detailed records
egarding deaths, hospitalizations, and procedures, includ-
ng those at hospitals outside of KPNC. Confirmation of
ital status was performed via a query of the California
utomated mortality linkage system (35). Survival curves
ere estimated by the Kaplan-Meier method, and outcomes
f CABG-eligible patients were compared with outcomes
f CABG-ineligible patients using the log-rank test.
Our sample size and the number of events precluded a full
ultivariable assessment of whether surgical ineligibility or
he presence of any non-NCDR–measured risk factor were
ndependent predictors of outcome. However, risk scores
elying upon traditionally measured risk factors such as the
uroSCORE have been shown to predict long-term out-omes in patients undergoing surgical and percutaneous
reatment of ULM disease (36,37). Therefore, we tested
hether surgical ineligibility or the presence of any non-
CDR–measured risk factor remained independent predictors
f outcomes when included as predictor variables along with
redicted mortalities (as continuous covariates) from the Eu-
oSCORE, STS model, and NCDR Cath-PCI mortality risk
odel in Cox proportional hazards models. Verification of
he proportional hazards assumption was performed using the
ethods of Grambsch and Therneau (38). Finally, given the
ong time interval of the study period, we tested whether there
as an interaction with treatment year and surgical ineligibility.
o temporal effect was observed.
Statistical analyses were performed using Stata version 11
StataCorp, College Station, Texas).
esults
Study population. During the study period, 142 patients
nderwent ULM PCI. Thirty-eight were excluded for
ardiogenic shock or ST-segment elevation myocardial in-
arction, and 3 were excluded for ongoing ischemic pain.
he remaining 101 patients who underwent nonemergent
CI for ULM disease comprised the study cohort.
Classiﬁcation of patients undergoing ULM PCI according to
surgical eligibility. Explicit documentation of surgical inel-
gibility dictating the decision to perform ULM PCI was
resent in 55 of 101 patients. Initial interobserver agree-
ent for this classification occurred in 92% of the patients,
ith a kappa statistic of 0.82 (indicative of very good
greement). At least 1 reason for surgical ineligibility was
ited for each of the 55 patients and multiple reasons were
ommon (Online Appendix 2). Reasons identified for CABG
neligibility are categorized in Figure 1.
Comparison of CABG-eligible patients with CABG-ineligible
patients. Baseline characteristics, procedural variables, and
ischarge medications are compared between CABG-
neligible and CABG-eligible patients in Table 1. CABG-
neligible patients had a greater prevalence of traditionally
easured risk factors, including higher STS scores, NCDR
ath-PCI risk scores, and EuroSCOREs.
The prevalence of non-NCDR–captured clinical condi-
ions in both groups is presented in Table 2. At least 1
on-NCDR–captured condition was present in 78% of the
ABG-ineligible patients and in 22% of those classified as
ABG-eligible. We considered cachexia/frailty be a non-
CDR–measured risk factor. Although the NCDR mea-
ures height and weight, the mean body mass index of
atients with cachexia/frailty was 24  9.4 kg/m2 and
within the normal range for all but 1 patient (range 19.6 to
26.7 kg/m2).
Association of surgical eligibility with clinical outcomes. The
median follow-up until death or the last documented
physical encounter was 540 days. One-year follow-up was
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1023available for 92% of the patients. There were 2 in-hospital
deaths. In general, CABG-ineligible patients were more
likely to die (hazard ratio [HR]: 7.7, 95% confidence
interval [CI]: 1.8 to 33) or experience the combined
endpoint of death, myocardial infarction, or stroke (HR:
3.0, 95% CI: 1.2 to 7.4) (Fig. 2). There was no significant
difference in repeat revascularizations for CABG-ineligible
patients compared with CABG-eligible patients. Two pa-
tients underwent subsequent CABG (both were initially
classified as CABG-eligible), and the remaining patients
underwent repeat PCI (11 CABG-ineligible patients and
13 CABG-eligible patients). The presence of any non-
NCDR–captured condition also predicted a markedly in-
creased hazard of death on univariate analysis (HR: 5.3,
95% CI: 1.5 to 18) (Table 3). After adjusting for Euro-
SCORE, STS score, or NCDR Cath-PCI mortality risk in
Cox proportional hazards models, surgical ineligibility re-
mained an independent predictor of mortality (HR: 5.4,
95% CI: 1.2 to 25 adjusted for STS score; HR: 5.9, 95% CI:
1.3 to 27 adjusted for EuroSCORE; HR: 6.2, 95% CI: 1.4
Figure 1. Taxonomy of Reasons Cited for CABG Ineligibility
Contraindications for coronary artery bypass graft (CABG) surgery cited in the
medical records of 55 patients with explicit documentation of CABG ineligibil-
ity who underwent unprotected left main (ULM) percutaneous coronary inter-
vention (PCI) as an alternative to CABG. (Displayed in percentages. Multiple
reasons per patient were common.) PAD  peripheral artery disease.to 27 adjusted for NCDR risk model) (Table 4). Thepresence of any non-NCDR–measured risk factor also
remained an independent predictor of mortality after ad-
justment for the risk scores.
Discussion
Treatment selection bias and the potential for confounding
by indication. Comparing the outcomes of alternative treat-
ents in observational populations is challenging, primarily
Table 1. Baseline Characteristics, Procedural Data,
and Discharge Medications
CABG Ineligible
(n  55)
CABG Eligible
(n  46) p Value
Age, yrs 75 10 73 11 0.24
Male 36 (66%) 36 (78%) 0.16
Caucasian 38 (69%) 36 (78%) 0.30
Body mass index, kg/m2 27 10 28 7.3 0.93
Diabetes 26 (47%) 11 (24%) 0.02
Diabetes—insulin 5 (9.1%) 1 (2.2%) 0.14
Hypertension 48 (87%) 41 (89%) 0.77
Hyperlipidemia 50 (91%) 43 (93%) 0.63
Tobacco history 25 (47%) 18 (45%) 0.84
Prior myocardial infarction 29 (53%) 12 (26%) 0.007
History congestive heart failure 28 (51%) 2 (4.4%) <0.001
Ejection fraction, % 45 17 61 7 <0.0001
Prior PCI 5 (9.1%) 10 (22%) 0.10
Peripheral vascular disease 14 (25%) 9 (20%) 0.48
Cerebrovascular disease 13 (24%) 5 (11%) 0.12
History of renal insufﬁciency 9 (16%) 2 (4.4%) 0.06
Dialysis 5 (9.1%) 1 (2%) 0.22
Chronic lung disease 18 (33%) 7 (15%) 0.06
Serum creatinine, dialysis excluded 1.1 (0.9–1.4) 1.0 (0.9–1.1) 0.02*
Stable angina 12 (22%) 20 (43%) 0.02
Non–ST-segment elevation MI 34 (62%) 17 (37%) 0.006
Unstable angina 9 (16%) 9 (20%) 0.68
Class IV CHF 16 (29%) 8 (18%) 0.24
EuroSCORE, logistic 13.1 (5.5–30) 4.0 (1.9–12) <0.0001*
STS mortality risk 3.9 (2.3–11) 1.1 (0.5–2.9) <0.0001*
NCDR cath-PCI mortality risk 1.25 (0.36–3.3) 0.29 (0.14–1.1) 0.001*
Left main  3-vessel disease 40 (73%) 18 (39%) 0.001
Drug-eluting stent used 49 (93%) 47 (96%) 0.66
Discharge beta-blocker 48 (91%) 44 (96%) 0.33
Discharge ACE inhibitor/ARB 38 (77%) 38 (83%) 0.20
Discharge statin 51 (93%) 44 (96%) 0.89
Discharge aspirin 53 (96%) 46 (100%) 1.0
Discharge clopidogrel 53 (96%) 46 (100%) 1.0
Values aremean SD, n (%), ormedian (interquartile range). Comparison of patientswith explicit
documentation in themedical record of CABG ineligibility dictating decision to performULM PCI
(“CABG ineligible”) with those without documentation of surgical ineligibility (“CABG eligible”).
Bold p values are statistically significant. *Probability |Z| score Wilcoxon rank-sum test.
ACE  angiotensin-converting enzyme; ARB  angiotensin-receptor blocker; CABG  coro-
nary artery bypass graft; CHF  congestive heart failure; EuroSCORE  European System for
Cardiac Operative Risk Evaluation; MImyocardial infarction; NCDR National Cardiovascular
Data Registry; PCI  percutaneous coronary intervention; STS  Society of Thoracic Surgeons;ULM unprotected left main.
(MI), or stroke. (C) Repeat revascularization. Abbreviations as in Figure 1.
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1024because treatment is not randomly assigned and there are
often important clinical reasons for preferring 1 treatment
over another. Our study exemplifies this problem in the
context of nonemergent PCI for ULM disease. A careful
review of clinical data revealed comorbid risk factors that
dictated treatment selection in most patients. Patients who
underwent ULM PCI because they were felt to be ineligible
for surgery had a higher prevalence of traditionally measured
risk factors including poor systolic function, acute presen-
tations, and diabetes. However, they also had a higher
prevalence of clinical conditions not measured by the
ACC–NCDR Cath-PCI registry but felt to be important
by treating physicians and surgeons. These included condi-
tions that potentially complicate CABG, such as aortic
calcification, as well as conditions associated with poor
long-term prognosis, such as cancer and cachexia/frailty.
Not surprisingly, the presence of these conditions was
associated with markedly worse outcomes. Because these
conditions are unmeasured by the ACC–NCDR Cath-PCI
registry and are associated with worse outcomes, they would
represent a significant source of potential confounding by
indication in any study comparing modes of revasculariza-
tion relying solely on ACC–NCDR data to adjust for
differences in baseline conditions.
Need to capture additional risk factors. Despite the com-
mon use of propensity scores to attenuate the impact of
treatment selection bias in observational studies capturing
only traditionally measured risk factors, there are limitations
of such an approach (39,40). Our findings suggest that
Table 2. Prevalence of Non-NCDR–Captured Clinical Conditions
CABG Ineligible
(n  55)
CABG Eligible
(n  46) p Value
Active malignancy 6 (11%) 0 (0%) 0.03
Dementia 2 (3.6%) 4 (8.7%) 0.41
Severe aortic calciﬁcation 6 (11%) 0 (0%) 0.03
End-stage liver disease 3 (5.5%) 0 (0%) 0.25
Poor targets/conduits 10 (18%) 3 (6.5%) 0.13
Extensive nonviable myocardium 3 (5.5%) 0 (0%) 0.24
Hematologic abnormality 7 (13%) 1 (2%) 0.07
Immobile/neuromuscular disease 4 (7.3%) 2 (4.4%) 0.69
Immunosuppressed 5 (9.1%) 1 (2.2%) 0.22
Cachexia/frailty 7 (13%) 0 (0%) 0.02
Chest/abdominal wall abnormality 2 (3.6%) 0 (0%) 0.50
Psychosis/encephalopathy 3 (5.5%) 0 (0%) 0.25
Gastrointestinal bleeding 3 (5.5%) 0 (0%) 0.25
Systemic infection 1 (1.8%) 0 (0%) 1.00
Severe pulmonary hypertension 4 (7.3%) 1 (2.2%) 0.37
Any non-NCDR risk factor 43 (78%) 10 (22%) <0.001
Values are n (%). Prevalence of conditions not captured by the NCDR Cath-PCI registry in patients
with or without explicit documentation in the medical record of surgical ineligibility dictating
choice to perform ULM PCI. Bold p values are statistically significant.
Abbreviations as in Table 1.incorporating additional risk factors should be considered,Figure 2. Impact of Documentation of CABG Ineligibility on Outcomes
of Patients Undergoing ULM PCI
Kaplan-Meier estimates comparing long-term outcomes in patients under-
going ULM PCI with prior documentation of surgical ineligibility in the
medical record (“CABG ineligible”) with those without such documentation
(“CABG eligible”). (A) All-cause mortality. (B) Death, myocardial infarction
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1025certainly for studies using clinical registries such as the
NCDR Cath-PCI registry. As an example, studies of
transcatheter aortic valve implantation are routinely collect-
ing reasons for inoperability including frailty, aortic calcifi-
cation, neoplasia, oxygen-dependent lung disease, and chest
wall deformity (41,42). Other studies of CABG populations
have demonstrated that “unconventional” risk factors such
as hypoalbuminemia and prior mediastinal radiation ad-
versely affect survival (43,44) and should likewise be con-
sidered as predictor variables in observational studies.
Whereas conditions such as frailty may seem difficult to
quantify, investigators have demonstrated that gait speed
was a reliable surrogate for frailty and independently pre-
dicted outcomes (45).
Broader implications. Although we restricted our analysis to
patients with ULM disease, it is likely that similar treatment
selection bias occurs in patients with multivessel coronary
Table 3. Predictors of All-Cause Mortality
Unadjusted HR 95% CI p Value
Ineligible for CABG 7.7 1.8–33.0 0.006
Any non-NCDR risk factor 5.3 1.5–18.0 0.008
Ejection fraction 35% 4.3 1.7–10.5 0.002
Malignancy 5.8 1.9–18.0 0.002
Cachexia/frailty 14.0 5.4–36.0 0.001
Immunosuppressed 6.1 2.0–18.0 0.001
STS score 3 7.8 2.3–27.0 0.001
NCDR Cath-PCI risk 2.0% 3.4 1.4–8.4 0.008
Non–ST-segment elevation MI 2.8 1.0–7.8 0.05
EuroSCORE 6 4.0 1.2–14.0 0.03
Liver disease 7.6 1.7–34.0 0.008
Renal insufﬁciency 4.2 1.6–11.0 0.004
Diabetes 3.3 1.3–8.3 0.01
History of CHF 5.5 2.1–15.0 0.001
Hematologic abnormality 7.9 2.7–23.0 0.001
Left main stent diameter, per mm 0.54 0.31–0.96 0.04
Predictors of mortality among all 101 patients undergoing ULM PCI on univariate analysis.
CI confidence interval; HR hazard ratio; other abbreviations as in Table 1.
Table 4. Adjusted HR for Death and Death, MI, or St
Death
HR (95% C
Adjusted for STS score
CABG ineligibility 5.4 (1.2–25
Any non-NCDR risk factor 6.1 (1.7–21
Adjusted for EuroSCORE, logistic
CABG ineligibility 5.9 (1.3–27
Any non-NCDR risk factor 4.8 (1.4–17
Adjusted for NCDR Cath-PCI risk model
CABG ineligibility 6.2 (1.4–27
Any non-NCDR risk factor 1.3 (1.1–1.6
Bold p values are statistically significant.Abbreviations as in Tables 1 and 3.disease without left main involvement. As PCI has emerged
as an alternative therapy for patients who are not candidates
for CABG, the impact of treatment selection bias should
also be considered in studies of appropriate-use criteria
relying on NCDR-derived data. Although prior studies
using adjusted NCDR data have shown that patients
undergoing PCI for indications rated as Class III in the
American College of Cardiology/American Heart Associa-
tion Guidelines have worse outcomes, the present analysis
provides insight into why treatments might be chosen in
apparent conflict with appropriate-use criteria or guidelines
as a substantial proportion of patients treated with PCI
likely lack a surgical alternative (46,47).
Study limitations. The major strength of our study is its
careful manual review of a comprehensive electronic medical
record allowing capture of a large number of predictor
variables. Nonetheless, important limitations need to be
considered when interpreting our findings. First, our patient
population comes from a single, large tertiary referral center
and may not be generalizable. In addition, the lack of
economic incentives in this staff-model integrated care
organization, as well as CABG outcomes reporting being
mandated by the state of California, might have had an
impact on physician behavior. Our analysis is also inherently
subjective and impossible to perform in a completely
blinded fashion, despite stringent coding definitions and
independent reviews. Moreover, even though medical re-
cords of all patients were reviewed a second time to
minimize ascertainment bias, we relied on documentation in
the medical record and did not prospectively collect these
data using standardized definitions. Building upon this
work, a supplement to the NCDR for ULM or multivessel
PCI could theoretically overcome these limitations in future
data collection efforts. Our sample size precluded full
multivariable adjustment with all available NCDR data and
it is possible that more complete adjustment might have
attenuated the outcome differences we identified between
CABG-eligible and -ineligible patients. However, there is
p Value
Death, MI, or Stroke
HR (95% CI) p Value
0.03 1.9 (0.72–5.3) 0.18
0.005 1.7 (0.75–3.9) 0.21
0.02 2.2 (0.82–5.8) 0.12
0.01 1.6 (0.69–3.6) 0.29
0.02 2.4 (0.94–6.1) 0.07
0.001 1.6 (0.72–3.7) 0.24roke
I)
)
)
)
)
)
)
11
1
1
1
1
1
1
1
1
2
2
2
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1026not much obvious correlation between the reasons we
identified for treatment choice and NCDR data elements,
and the observed effect sizes were large. Even though we
adjusted for the EuroSCORE, STS score, and a risk score
derived from the NCDR Cath-PCI registry, all of these
models were developed to predict short-term mortality (up
to 30 days in the NCDR model), and only the EuroSCORE
has been previously shown to predict long-term mortality in
patients undergoing ULM PCI (37). Finally, we chose to
use definitions from version 3 of the NCDR, as opposed to
the currently in-use version 4, because data using the earlier
version are being used in ongoing comparative effectiveness
studies such as ASCERT. However, the “non-NCDR–
captured” variables identified in the present analysis are also
not captured by version 4.
Conclusions
We found that most patients undergoing nonemergent
ULM PCI are ineligible for CABG as an alternative. The
reasons cited for ineligibility include conditions not cap-
tured by standard datasets, including by the largest national
PCI registry. These unmeasured clinical conditions may
represent a significant source of residual confounding for
studies comparing modes of revascularization. Whereas
registries such as ACC–NCDR Cath-PCI have served an
invaluable role in assessing quality, caution in the use of
these registries for comparative effectiveness studies is in
order, and specific analyses need to be scrutinized to ensure
that the observed differences in outcomes are not attribut-
able to important but unmeasured clinical characteristics.
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APPENDIX
For a list of variables extracted from the NCDR, EuroSCORE, and STS
scores, as well as patient-specific reasons for surgical ineligibility, please
see the online version of this paper.
